Leuprolide Acetate Depot Kit
Product Images NDC 69097-909

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Leuprolide Acetate Depot (NDC 69097-909). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Leuprolide Acetate Injection 01)

This text appears to be a list of various components and parts related to medical equipment such as syringes and vials. It includes items such as plunger, rod, backstop, syringe barrel, vial adapter, needle, flip-off button, and vial.*

FDA Label Image

Figure 2 (Leuprolide Acetate Injection 02)

FDA Label Image

Figure 3 (Leuprolide Acetate Injection 03)

FDA Label Image

Figure 4 (Leuprolide Acetate Injection 04)

FDA Label Image

Figure 5 (Leuprolide Acetate Injection 05)

FDA Label Image

Figure 6 (Leuprolide Acetate Injection 06)

FDA Label Image

Figure 7 (Leuprolide Acetate Injection 07)

FDA Label Image

Figure 7 (Leuprolide Acetate Injection 08)

FDA Label Image

Figure 7 (Leuprolide Acetate Injection 09)

FDA Label Image

Figure 7 (Leuprolide Acetate Injection 10)

FDA Label Image

Chemical Structure Of Leuprolide Acetate (Leuprolide Acetate Injection 11)

FDA Label Image

Figure 12 (Leuprolide Acetate Injection 12)

FDA Label Image

Figure 12 (Leuprolide Acetate Injection 13)

FDA Label Image

Label A (Leuprolide Acetate Injection 14)

Leuprolide acetate for depot suspension is a medication that requires reconstitution before being used for intramuscular injection. The recommended dose is one injection every three months. The medication is stored in a controlled room temperature between 20°C to 25°C with excursions permitted between 15°C to 30°C. The medication is manufactured by GPharm, SA and comes in a single vial containing 225g and packaged in a carton. The dosage and administration procedures can be found in the package insert.*

FDA Label Image

Label B (Leuprolide Acetate Injection 15)

This is a description of a medication in the form of a 2 mL mannitol solution for intramuscular injection. It is intended for reconstitution of Leuprolide igé acetate Depot g3 and is only available with a prescription. The solution should be stored at 20°-25°C (68°-77°F). The text also includes the size of the needle (24mm) and the fact that the solution does not contain the active substance LOQS,VBZP. The other text appears to be information regarding the packaging and labeling of the medication.*

FDA Label Image

Label C (Leuprolide Acetate Injection 16)

This is a sterile Depot suspension medication called Leuprolide Acetate Pejivers. Each suspension contains 22.5mg of Leuprolide Acetate. It is manufactured and distributed by Cipla and is available by prescription only. This medication should be stored at a temperature between 20°C-25°C (68°F-77°F).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.